Psychedelics for the Treatment of Substance Use Disorder
Berta Fumàs, David Pubill, Raúl López‐arnau, Núria Nadal‐gratacós
Pharmaceutical science. October 13, 2025 DOI: 10.5772/intechopen.1012870 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction MDMA Psilocybin |
| Keywords | Mental health Psychosocial Substance use Hallucinogen Depression economics Substance abuse Psychotherapist Psychoactive substance Clinical psychology Drug Methadone |
| Key findings | Reviews the potential of psychedelics like psilocybin and ibogaine for treating substance use disorder through mechanisms involving neuroplasticity and psychological experiences. |
Abstract
Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as methadone and buprenorphine, used for opioid use disorder, may pose risks of dependency, overdose, and withdrawal, highlighting the need for innovative therapeutic approaches. Psychedelics, including psilocybin and ibogaine, have gained renewed scientific interest for their therapeutic potential in treating various mental health conditions such as depression and post-traumatic stress disorder. Building on these findings, researchers are exploring their potential in SUD treatment, particularly in facilitating recovery and long-term behavioral change. These compounds may facilitate therapeutic outcomes through mechanisms involving neuroplasticity, altered brain connectivity, and profound psychological experiences that support behavioral modification and emotional resilience. Beyond reducing substance use, psychedelics may enhance psychosocial functioning and overall mental health. This chapter will review their underlying mechanisms, clinical evidence, and future prospects in the treatment of SUD.